METHODS: A total of six conserved peptides representing B- and T-cell epitopes of Influenza A were identified and they were formulated in either incomplete Freund's adjuvant containing CpG ODN 1826 or being encapsulated in PLGA nanoparticles for the evaluation of immunogenicity in BALB/c mice.
RESULTS: The self-adjuvanting PLGA nanoparticles encapsulating the six conserved peptides were capable of eliciting the highest levels of IgG and IFN- γ producing cells. In addition, the immunogenicity of the six peptides encapsulated in PLGA nanoparticles showed greater humoral and cellular mediated immune responses elicited by the mixture of six naked peptides formulated in incomplete Freund's adjuvant containing CpG ODN 1826 in the immunized mice. Peptide 3 from the mixture of six peptides was found to exert necrotic effect on CD3+ T-cells and this finding indicated that peptide 3 should be removed from the nanovaccine formulation.
CONCLUSION: The study demonstrated the self-adjuvanting properties of the PLGA nanoparticles as a delivery system without the need for incorporation of toxic and costly conventional adjuvants in multi-epitope peptide-based vaccines.
METHODS: This study uses a designed guide RNA targeting the TRIB2 gene assembled via In-vitro synthesis. The gRNA with Cas9 protein leads to the formation of CRISPR-RNP structures, which target and cleave the TRIB2 gene. The assembled CRISPR-RNP system is transfected into target AML cell and control cell lines (i.e. HEK cells), and the subsequent gene cleavage and resulting changes to the AML cells in terms of cellular safety/tolerability and gene knockdown efficacy were studied via RT-qPCR, flow cytometry, and cell viability analysis.
RESULTS: The outcome demonstrates the well-tolerated transfection of the in-vitro assembled CRISPR RNP system with no signs of cellular toxicity and disruptions towards the AML cell's metabolic activities, promoting the safety aspects of CRISPR RNP post-transfection to human cells. The study further highlights the in-vitro efficacy of the CRISPR RNP in targeting the TRIB2 oncogene, where a statistically significant gene knockdown of more than 80% was detected via qPCR analysis of TRIB2 gene expression with minimal to no background effects from individual RNP components, equating to their targeted gene cleavage effects. In addition, the CRISPR TRIB2 gene knockdown also indicated the possibilities of induced AML cell death measured via flow cytometry markers, translating to favourable outcomes in eliminating cancerous growths.
CONCLUSIONS: This study research contributes to the refinement of the CRISPR-RNP strategy and preliminary evaluation for future clinical uses.
METHODS: Clinical trials from a targeted three-stage PubMed search, focusing on PCI indications, procedural timing, and device selection, were analyzed and integrated with consensus guidelines from leading cardiology organizations.
RESULTS: For patients presenting with ST-elevation myocardial infarction (STEMI), PCI is recommended within 12 h of the onset of symptoms, ideally achieving a door-to-balloon time of 90-120 min from the first medical contact. Beyond the 12 h mark, the procedure remains indicated for those exhibiting persistent ischemia, clinical symptoms, or complications such as shock, arrhythmia, or heart failure. In cases of non-STEMI (NSTEMI), patients generally benefit from PCI during their initial hospital stay, although an early invasive approach may not provide clinical advantages for frail elderly individuals. Complete revascularization is typically favored over treating only the culprit lesion, except in instances of cardiogenic shock. For those with chronic coronary syndrome (CCS), while PCI enhances quality of life and improves symptom management, most clinical trials report that it does not significantly reduce mortality or major cardiovascular incidents. The initial plain old balloon angioplasty faced complications of restenosis and acute vessel closure. While bare metal stents addressed acute closure, the problem of restenosis persisted and stent thrombosis was noted. Current drug-eluting stents (DESs) are the preferred choice owing to superior clinical outcomes, with lower restenosis and stent thrombosis rates. Although theoretically ideal, bioresorbable scaffolds (BRSs) are still undergoing further research since they have yet to prove superior to DESs in clinical trials. In addition, drug-coated balloons (DCBs) have become a specialized treatment, especially for managing in-stent restenosis.
CONCLUSION: The necessity for and timing of PCI are dictated by the patient's specific clinical presentation. Immediate intervention is critical for STEMI patients, within 12 h of onset, or those with complications, while NSTEMI cases should be treated during the hospital admission. For CCS, PCI serves as an elective option to alleviate symptoms without altering long-term survival. The DES remains the primary tool in modern PCI, with BRS still undergoing research trials and DCBs serving specialized roles.
METHODS: This cross-sectional study was conducted from July to August 2023 at four public hospitals in Sarawak, Malaysia. Universal sampling was used to recruit nurses from various critical care units managing patients requiring ventilator support. A self-administered questionnaire, consisting of four sections, was employed to gather background information from nurses, assess their knowledge, self-reported practices, and identify barriers related to VAP prevention.
RESULTS: A total of 298 critical care nurses participated in the study. Of these, 66.8% demonstrated poor knowledge of ventilator-associated pneumonia (VAP) prevention; however, self-reported practices with VAP prevention were significantly high at 76.5%. A Pearson's correlation test revealed a significant association between the nurses' knowledge and their self-reported practices related to VAP prevention (p
METHODS: The present study employed network pharmacology and topology approaches to establish a "herbal ingredients-active phytochemicals-target interaction" network to explore the potential therapeutic targets of SZKJT-active phytochemicals in the treatment of OSCC. The role of the target proteins in oncogenesis was assessed via GO and KEGG enrichment analyses, and their interactions with the active phytochemicals of SZKJT were calculated via molecular docking and dynamic simulations. The pharmacokinetic properties and toxicity of the active phytochemicals were also predicted. RESULTS: A total of 171 active phytochemicals of SZKJT fulfilled the bioavailability and drug-likeness screening criteria, with the flavonoids quercetin, kaempferol, and naringenin having the greatest potential. The 4 crucial targets of these active phytochemicals are PTGS2, TNF, BCL2, and CASP3, which encode cyclooxygenase-2, tumor necrosis factor (TNF), BCL-2 apoptosis regulator, and caspase-3, respectively. The interactions between phytochemicals and target proteins were predicted to be thermodynamically feasible and stable via molecular docking and dynamics simulations. Finally, the results revealed that the IL-6/JAK/STAT3 pathway and TNF signaling via NF-κB are the two prominent pathways targeted by SZKJT.
CONCLUSION: In summary, this study provides computational data for in-depth exploration of the mechanism by which SZKJT activates phytochemicals to treat OSCC.
OBJECTIVE: To evaluate weight loss outcomes, metabolic outcomes, and clinical predictors of treatment response following bariatric surgery in a large Asian cohort, with longitudinal follow-up up to five years in a selected subgroup of completers.
METHODS: This retrospective cohort study analyzed 1,478 adult patients who underwent primary bariatric surgery (laparoscopic sleeve gastrectomy [LSG], Roux-en-Y gastric bypass [RYGB], or one-anastomosis gastric bypass [OAGB]) between 2012 and 2022 at a single tertiary academic center in Malaysia. The primary outcome was percentage total weight loss (%TWL) at 1, 3, and 5 years, analyzed using an available-case approach. Pre-specified attrition analysis compared the characteristics of 5-year completers with non-completers. Secondary outcomes included longitudinal changes in glycated hemoglobin (HbA1c), blood pressure, and LDL cholesterol, with paired and cross-sectional analyses reported separately. Glycaemic outcome thresholds (HbA1c
METHODS: Thirty-seven patients were randomized to receive SCEA (n = 19) or placebo (n = 18) during colonoscopy. Additional rescue sedation was administered to patients if they had pain or discomfort during the procedure. Visual analogue scale was used to quantify the intensity of pain from the beginning to end of the procedure. Other variables analysed were the amount of sedation used, duration from start to caecal intubation, length of time for completion of colonoscopy and recovery time to home discharge.
RESULTS: Patients who received SCEA had a lower median pain score of 4.6 (interquartile range 5.7) compared to the placebo group of 6.0 (interquartile range 3.2). Statistical analysis comparing the groups revealed a non-significant P-value of 0.12, although more than 90% of the patients indicated willingness for SCEA as the primary analgesia if they were to repeat the procedure. Throughout the study, there were no adverse complications that occurred during the use of SCEA.
CONCLUSIONS: Even though this study did not demonstrate, a significance in pain reduction, SCEA remains a safe modality which, more than 90% of patients favoured as a substitute for pain relief during colonoscopy.
METHODS: We examined e-cigarette market data from the Euromonitor Global Market Information Database (GMID) Passport database, searched in the academic literature, grey literature and news archives for any reports or studies of e-cigarette related diseases or injuries, e-cigarette marketing, and e-cigarette policy responses in Southeast Asian countries, and browsed the websites of online e-cigarette retailers catering to the region's active e-cigarette markets.
RESULTS: In 2019, e-cigarettes were sold in six Southeast Asian markets with a total market value of $595 million, projected to grow to $766 million by 2023. E-commerce is a significant and growing sales channel in the region, with most of the popular or featured brands in online shops originating from China. Southeast Asian youth are targeted with a wide variety of flavours, trendy designs and point of sale promotions, and several e-cigarette related injuries and diseases have been reported in the region. Policy responses vary considerably between countries, ranging from strict bans to no or partial regulations.
CONCLUSION: Although Southeast Asia's e-cigarette market is relatively nascent, this is likely to change if transnationals invest more heavily in the region. Populous countries with weak e-cigarette regulations, notably Indonesia, Malaysia, Vietnam and the Philippines, are desirable targets for the transnationals. Regulatory action is needed to prevent e-cigarette use from becoming entrenched into these societies, especially among young people.